MDS 2021 | Key advances in MDS management
Sandra Kurtin
• 22 Sep 2021
Sandra Kurtin, PhD, ACNP-BC, AOCN, University of Arizona, Tucson, AZ, outlines the key advances in the management of myelodysplastic syndromes (MDS), including the identification of new therapeutic targets, improvements in our understanding of the main drivers of MDS, and enhanced support for patients. This interview took place at the 16th International Congress on Myelodysplastic Syndromes, held virtually in 2021.
